Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

EFGARTIGIMOD ALFA vs ROZANOLIXIZUMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

EFGARTIGIMOD ALFA vs ROZANOLIXIZUMAB: Safety Overview

Metric EFGARTIGIMOD ALFA ROZANOLIXIZUMAB
Total FAERS Reports 249 303
Deaths Reported 26 9
Death Rate 10.4% 3.0%
Hospitalizations 115 114
Average Patient Age 54.0 yrs 61.3 yrs
% Female Patients 82.5% 60.9%
Manufacturer argenx US UCB, Inc.
Route INTRAVENOUS SUBCUTANEOUS
Marketing Status Prescription N/A